Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records
详细信息 查看全文
- 作者：Kevin Wing1 ; kevin.wing@lshtm.ac.uk" class="auth_mail ; Ian Douglas1 ; Krishnan Bhaskaran1 ; Olaf H. Klungel2 ; 6 ; Robert F. Reynolds3 ; Munir Pirmohamed4 ; Liam Smeeth1 ; Tjeerd P. van Staa1 ; 2 ; 5
- 刊名：Drug Discovery Today
- 出版年：April 2014
- 年：2014
- 卷：19
- 期：4
- 页码：361-366
- 全文大小：344 K
文摘
- •
Serious adverse drug reactions can lead to the withdrawal of licensed drugs.
- •
Predictive genetic tests exist for a limited number of adverse drug reactions.
- •
Obtaining patients and genetic samples for test development is challenging.
- •
Electronic health record databases could be exploited to overcome these barriers.
- •
Genetic test effectiveness could also be assessed using these databases.